81 related articles for article (PubMed ID: 11062729)
1. Concentration-dependent variable effects of etoposide on the cell cycle of CML cells.
Fukumi S; Horiguchi-Yamada J; Iwase S; Ohno T; Yamada H
Anticancer Res; 2000; 20(5A):3105-10. PubMed ID: 11062729
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
5. The modulation of radiation-induced cell death by genistein in K562 cells: activation of thymidine kinase 1.
Jeong MH; Jin YH; Kang EY; Jo WS; Park HT; Lee JD; Yoo YJ; Jeong SJ
Cell Res; 2004 Aug; 14(4):295-302. PubMed ID: 15353126
[TBL] [Abstract][Full Text] [Related]
6. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
7. New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.
Higginbottom K; Jahnke U; Newland AC; Cotter FE; Allen PD
Apoptosis; 2007 Oct; 12(10):1847-55. PubMed ID: 17636382
[TBL] [Abstract][Full Text] [Related]
8. Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
López-Lázaro M; Pastor N; Azrak SS; Ayuso MJ; Cortés F; Austin CA
Leuk Res; 2006 Jul; 30(7):895-8. PubMed ID: 16387358
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Rosato RR; Almenara JA; Grant S
Cancer Res; 2003 Jul; 63(13):3637-45. PubMed ID: 12839953
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor).
Chen Y; Su YH; Wang CH; Wu JM; Chen JC; Tseng SH
Anticancer Res; 2005; 25(6B):4203-8. PubMed ID: 16309217
[TBL] [Abstract][Full Text] [Related]
12. Relationship between cell cycle changes and variations of the mitochondrial membrane potential induced by etoposide.
Facompré M; Wattez N; Kluza J; Lansiaux A; Bailly C
Mol Cell Biol Res Commun; 2000 Jul; 4(1):37-42. PubMed ID: 11152626
[TBL] [Abstract][Full Text] [Related]
13. Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status.
Zhao S; Tsuchida T; Kawakami K; Shi C; Kawamoto K
Int J Oncol; 2002 Jul; 21(1):49-55. PubMed ID: 12063549
[TBL] [Abstract][Full Text] [Related]
14. Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells.
Lee SJ; Cho YH; Park K; Kim EJ; Jung KH; Park SS; Kim WJ; Moon SK
Biochem Pharmacol; 2008 Jun; 75(12):2289-300. PubMed ID: 18468578
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
16. Cellular response to etoposide treatment.
Montecucco A; Biamonti G
Cancer Lett; 2007 Jul; 252(1):9-18. PubMed ID: 17166655
[TBL] [Abstract][Full Text] [Related]
17. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions.
Scovassi AL; Pellegata NS; Di Stefano L; Padovan L; Negri C; Prosperi E; Riva F; Ciomei M; Ranzani GN
Anticancer Res; 2001; 21(4A):2803-8. PubMed ID: 11724358
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II inhibition differentially modulates Caco-2 intestinal epithelial cell phenotype.
Rashid Z; Basson MD
Biochem Biophys Res Commun; 1996 Feb; 219(1):82-8. PubMed ID: 8619832
[TBL] [Abstract][Full Text] [Related]
19. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.
Liu WM; Joel SP
Cancer Chemother Pharmacol; 2003 Apr; 51(4):291-6. PubMed ID: 12721756
[TBL] [Abstract][Full Text] [Related]
20. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.
Chiu CC; Li CH; Ung MW; Fuh TS; Chen WL; Fang K
Cancer Lett; 2005 Jun; 223(2):249-58. PubMed ID: 15896459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
